Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
In this interview, Ana Ormaza Vera, MD, discusses findings from a study she presented at the American College of Cardiology’s 74th Annual Scientific Session & Expo on March 29, 2025, in Chicago. She...
In this interview, Ying-Ying Leung, MB, ChB, MD, answers questions about her team’s recently published article titled “Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One...
Ikuo Hirano, MD, the Chair of the Writing Committee, answers questions about the ACG/JTF guidelines on the management of patients with eosinophilic esophagitis.
In a new study, researchers sought to clarify how the gut microbe may influence chronic gastrointestinal disease. The coauthors Michael C. Hoaglin, MD, and Melissa Agnello, PhD, answered our questions about...
Edward L. Barnes MD MPH, from the University of North Carolina at Chapel Hill, answers questions about the management of pouchitis in ulcerative colitis, a topic he discussed during his session at the...
While SGLT-2 inhibitors are often used in patients with type 2 diabetes, this class of medication can also be used to treat patients with heart failure. In this Q&A, Jennifer Clements, PharmD, discusses a...
The authors of a recent study examined the safety and clinical efficacy of using mepolizumab to treat patients with HES. First author Florence Roufosse, MD, PhD, answered Consultant360’s questions on the...
Generic medications are becoming an increasingly hot topic, as the cost of prescriptions rise. The authors of a recent study sought to examine the attitudes of health care providers on prescribing generic...
